ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Clinical trial NCT05014464 · RECRUITING

Trial details

NCT number: NCT05014464
Sponsor: Hunan Province Tumor Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2021-11-13
Primary completion: 2026-06-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.